Evidence map›Paper›PMID 36890264›Full record

ArticleScientific reports2023

Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe.

Timothy L Wiemken, Farid Khan, Laura Puzniak, Wan Yang, Jacob Simmering, Philip Polgreen, Jennifer L Nguyen, Luis Jodar, John M McLaughlin

2 registry-linked trialsAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 89 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06207929 completednot on this mapstarted 2024, after this paper: background citation

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

TypeobservationalSponsorEvidation HealthRan2024 to 2024Enrolled18,157ConditionsInfluenza, Human, COVID-19, Influenza A, Influenza B
NCT06229444 nacompletednot on this mapstarted 2024, after this paper: background citation

Predict + Protect: A Randomized Controlled Trial Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to Influenza-like Illness (ILI)

TypeinterventionalSponsorEvidation HealthRan2024 to 2024Enrolled17,043ConditionsInfluenza, Influenza A, Influenza B, COVID-19ArmsILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Timothy L WiemkenPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA. timothy.wiemken@pfizer.com.
Farid KhanPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA.
Laura PuzniakPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA.
Wan YangColumbia University Mailman School of Public Health-Epidemiology, 722 West 168th St., New York, NY, 10032, USA.
Jacob SimmeringDepartment of Internal Medicine-Pulmonary, Critical Care, and Occupational Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Philip PolgreenDepartment of Internal Medicine-Infectious Diseases, University of Iowa, Iowa City, IA, 52242, USA.
Jennifer L NguyenPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA.
Luis JodarPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA.
John M McLaughlinPfizer Inc., 500 Arcola Rd., Collegeville, PA, 19426, USA. john.mclaughlin@pfizer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining whether SARS-CoV-2 exhibits seasonality like other respiratory viruses is critical for public health planning. We evaluated whether COVID-19 rates follow a seasonal pattern using time series models. We used time series decomposition to extract the annual seasonal component of COVID-19 case, hospitalization, and mortality rates from March 2020 through December 2022 for the United States and Europe. Models were adjusted for a country-specific stringency index to account for confounding by various interventions. Despite year-round disease activity, we identified seasonal spikes in COVID-19 from approximately November through April for all outcomes and in all countries. Our results support employing annual preventative measures against SARS-CoV-2, such as administering seasonal booster vaccines in a similar timeframe as those in place for influenza. Whether certain high-risk individuals may need more than one COVID-19 vaccine booster dose each year will depend on factors like vaccine durability against severe illness and levels of year-round disease activity.

Indexed as

COVID-19COVID-19 VaccinesEuropeHospitalizationHumansImmunization, SecondarySARS-CoV-2SeasonsUnited StatesCOVID-19 Vaccines

Identifiers

PMID36890264
PMCPMC9994397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.